Colorectal carcinoma (CRC) · line 2 · Encorafenib + Cetuximab (BEACON CRC)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	2
Track	aggressive
Linked regimen	`REG-ENCORAFENIB-CETUXIMAB`

ID	`IND-CRC-METASTATIC-2L-BRAF-BEACON`
Type	Indication
Status	reviewed 2026-04-26 \| pending_clinical_signoff
Diseases	`DIS-CRC`
Sources	`SRC-ESMO-COLON-2024` `SRC-NCCN-COLON-2025`

Notes

BRAF V600E mCRC 2L+ targeted track. 1L for BRAF V600E remains FOLFOX+bev or FOLFOXIRI+bev intensification.

Used By

Algorithms

ALGO-CRC-METASTATIC-2L - ALGO-CRC-METASTATIC-2L

Indication

IND-CRC-METASTATIC-2L-FOLFIRI-BEV - IND-CRC-METASTATIC-2L-FOLFIRI-BEV
IND-CRC-METASTATIC-3L-TAS102-BEV - IND-CRC-METASTATIC-3L-TAS102-BEV
IND-CRC-METASTATIC-MAINT-FOLFIRI-BEV - IND-CRC-METASTATIC-MAINT-FOLFIRI-BEV